BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1111 related articles for article (PubMed ID: 12755637)

  • 41. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers.
    Zerzankova L; Kostrhunova H; Vojtiskova M; Novakova O; Suchankova T; Lin M; Guo Z; Kasparkova J; Brabec V
    Biochem Pharmacol; 2010 Aug; 80(3):344-51. PubMed ID: 20399754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
    Malina J; Natile G; Brabec V
    Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands.
    Boccarelli A; Coluccia M; Intini FP; Natile G; Locker D; Leng M
    Anticancer Drug Des; 1999 Jun; 14(3):253-64. PubMed ID: 10500500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 1,2-GG intrastrand cross-link of antitumor dinuclear bifunctional platinum compound with spermidine linker inhibits DNA polymerization more effectively than the cross-link of conventional cisplatin.
    Moriarity B; Nováková O; Farrell N; Brabec V; Kaspárková J
    Arch Biochem Biophys; 2007 Mar; 459(2):264-72. PubMed ID: 17224122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
    Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
    Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative studies on the mechanism of cytotoxic action of novel platinum II complexes with pyrazole ligands.
    Ciesielska E; Szulawska A; Studzian K; Ochocki J; Malinowska K; Kik K; Szmigiero L
    J Inorg Biochem; 2006 Oct; 100(10):1579-85. PubMed ID: 16842854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of bridging ligands in determining DNA-binding ability and cross-linking patterns of dinuclear platinum(II) antitumour complexes.
    Zhu J; Lin M; Fan D; Wu Z; Chen Y; Zhang J; Lu Y; Guo Z
    Dalton Trans; 2009 Dec; (48):10889-95. PubMed ID: 20023919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions.
    Brabec V; Pracharova J; Novakova O; Gibson D; Kasparkova J
    Dalton Trans; 2015 Feb; 44(8):3573-82. PubMed ID: 25406573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands.
    Zorbas-Seifried S; Jakupec MA; Kukushkin NV; Groessl M; Hartinger CG; Semenova O; Zorbas H; Kukushkin VY; Keppler BK
    Mol Pharmacol; 2007 Jan; 71(1):357-65. PubMed ID: 17050805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
    Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
    J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
    Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
    ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
    Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
    J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand.
    Marqués-Gallego P; Contaldi S; den Dulk H; Monari M; Brouwer J; Jaehde U; Kalayda GV; Reedijk J
    J Inorg Biochem; 2009 Dec; 103(12):1602-8. PubMed ID: 19783310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.